Loading…
Pharmacological targeting of Sam68 functions in colorectal cancer stem cells
Cancer stem cells (CSCs) are documented to play a key role in tumorigenesis and therapy resistance. Despite significant progress in clinical oncology, CSC reservoirs remain elusive and difficult to eliminate. Reverse-turn peptidomimetics were characterized as disruptors of CBP/beta-Catenin interacti...
Saved in:
Published in: | iScience 2021-12, Vol.24 (12), p.103442-103442, Article 103442 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c498t-6b047c64d73ad4aa2a0681e613b7d3a5668ad482dba1084cdc6bc21f654cac923 |
---|---|
cites | cdi_FETCH-LOGICAL-c498t-6b047c64d73ad4aa2a0681e613b7d3a5668ad482dba1084cdc6bc21f654cac923 |
container_end_page | 103442 |
container_issue | 12 |
container_start_page | 103442 |
container_title | iScience |
container_volume | 24 |
creator | Masibag, Angelique N. Bergin, Christopher J. Haebe, Joshua R. Zouggar, Aïcha Shah, Muhammad S. Sandouka, Tamara Mendes da Silva, Amanda Desrochers, François M. Fournier-Morin, Aube Benoit, Yannick D. |
description | Cancer stem cells (CSCs) are documented to play a key role in tumorigenesis and therapy resistance. Despite significant progress in clinical oncology, CSC reservoirs remain elusive and difficult to eliminate. Reverse-turn peptidomimetics were characterized as disruptors of CBP/beta-Catenin interactions and represent a promising avenue to curb hyperactive canonical Wnt/beta-Catenin signaling in CSCs. Recent studies suggested Sam68 as a critical mediator of reverse-turn peptidomimetics response in CSC populations. Using computational and biochemical approaches we confirmed Sam68 as a primary target of reverse-turn peptidomimetics. Furthermore, we executed an in silico drug discovery pipeline to identify yet uncharacterized reverse-turn peptidomimetic structures displaying superior anti-CSC activity in transformed pluripotent and colorectal cancer cell models. Thus, we identified YB-0158 as a reverse-turn peptidomimetic small molecule with enhanced translational potential, altering key hallmarks of human colorectal CSCs in patient-derived ex vivo organoids and in vivo serial tumor transplantation.
[Display omitted]
•Sam68 is a direct protein target of reverse-turn peptidomimetic small molecules•YB-0158 is a peptidomimetic structure with high predicted affinity for Sam68•YB-0158 elicits a cancer-selective response impeding main cancer stem cell hallmarks•YB-0158 blocks cancer stem cell activity in tumor organoids and in vivo systems
Pharmacology; Biochemistry; Stem cells research; Cancer; |
doi_str_mv | 10.1016/j.isci.2021.103442 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_a4b364fa1b8740e1b8dceb3a7778dcb2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2589004221014139</els_id><doaj_id>oai_doaj_org_article_a4b364fa1b8740e1b8dceb3a7778dcb2</doaj_id><sourcerecordid>2608124490</sourcerecordid><originalsourceid>FETCH-LOGICAL-c498t-6b047c64d73ad4aa2a0681e613b7d3a5668ad482dba1084cdc6bc21f654cac923</originalsourceid><addsrcrecordid>eNp9UV1rFDEUDWKxZds_4NM8-rJrvjbJgAhSrBYWFGyfw82dzDTLzKQm2YL_3oxTxL4IIfdy7zkn5BxC3jK6Y5Sp98ddyBh2nHJWB0JK_opc8L1pt5RK_vqf_pxc5XyklPJ6ZKvekHMhjdaybS_I4fsDpAkwjnEICGNTIA2-hHloYt_8gEmZpj_NWEKccxPmZkEmj6VCEWb0qcnFTw36ccyX5KyHMfur57oh9zef766_bg_fvtxefzpsUbambJWjUqOSnRbQSQAOVBnmFRNOdwL2Spk6N7xzwKiR2KFyyFmv9hIBWy425HbV7SIc7WMKE6RfNkKwfwYxDRZSCTh6C9IJJXtgzmhJfS0deidAa107t2h9XLUeT27ydTmXBOML0ZebOTzYIT5Zo4Ro67Uh754FUvx58rnYqSZT7YDZx1O2XFHDuJQtrVC-QjHFnJPv_z7DqF1StUe7pGqXVO2aaiV9WEm-OvoUfLIV4avzXVhyqF8O_6P_BhWaqmg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2608124490</pqid></control><display><type>article</type><title>Pharmacological targeting of Sam68 functions in colorectal cancer stem cells</title><source>ScienceDirect®</source><source>NCBI_PubMed Central(免费)</source><creator>Masibag, Angelique N. ; Bergin, Christopher J. ; Haebe, Joshua R. ; Zouggar, Aïcha ; Shah, Muhammad S. ; Sandouka, Tamara ; Mendes da Silva, Amanda ; Desrochers, François M. ; Fournier-Morin, Aube ; Benoit, Yannick D.</creator><creatorcontrib>Masibag, Angelique N. ; Bergin, Christopher J. ; Haebe, Joshua R. ; Zouggar, Aïcha ; Shah, Muhammad S. ; Sandouka, Tamara ; Mendes da Silva, Amanda ; Desrochers, François M. ; Fournier-Morin, Aube ; Benoit, Yannick D.</creatorcontrib><description>Cancer stem cells (CSCs) are documented to play a key role in tumorigenesis and therapy resistance. Despite significant progress in clinical oncology, CSC reservoirs remain elusive and difficult to eliminate. Reverse-turn peptidomimetics were characterized as disruptors of CBP/beta-Catenin interactions and represent a promising avenue to curb hyperactive canonical Wnt/beta-Catenin signaling in CSCs. Recent studies suggested Sam68 as a critical mediator of reverse-turn peptidomimetics response in CSC populations. Using computational and biochemical approaches we confirmed Sam68 as a primary target of reverse-turn peptidomimetics. Furthermore, we executed an in silico drug discovery pipeline to identify yet uncharacterized reverse-turn peptidomimetic structures displaying superior anti-CSC activity in transformed pluripotent and colorectal cancer cell models. Thus, we identified YB-0158 as a reverse-turn peptidomimetic small molecule with enhanced translational potential, altering key hallmarks of human colorectal CSCs in patient-derived ex vivo organoids and in vivo serial tumor transplantation.
[Display omitted]
•Sam68 is a direct protein target of reverse-turn peptidomimetic small molecules•YB-0158 is a peptidomimetic structure with high predicted affinity for Sam68•YB-0158 elicits a cancer-selective response impeding main cancer stem cell hallmarks•YB-0158 blocks cancer stem cell activity in tumor organoids and in vivo systems
Pharmacology; Biochemistry; Stem cells research; Cancer;</description><identifier>ISSN: 2589-0042</identifier><identifier>EISSN: 2589-0042</identifier><identifier>DOI: 10.1016/j.isci.2021.103442</identifier><identifier>PMID: 34877499</identifier><language>eng</language><publisher>Elsevier Inc</publisher><subject>Biochemistry ; Cancer ; Pharmacology ; Stem cells research</subject><ispartof>iScience, 2021-12, Vol.24 (12), p.103442-103442, Article 103442</ispartof><rights>2021 The Author(s)</rights><rights>2021 The Author(s) 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c498t-6b047c64d73ad4aa2a0681e613b7d3a5668ad482dba1084cdc6bc21f654cac923</citedby><cites>FETCH-LOGICAL-c498t-6b047c64d73ad4aa2a0681e613b7d3a5668ad482dba1084cdc6bc21f654cac923</cites><orcidid>0000-0002-0832-5753 ; 0000-0002-4631-5812 ; 0000-0003-3610-6184 ; 0000-0002-6677-4020</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633986/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S2589004221014139$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,3549,27924,27925,45780,53791,53793</link.rule.ids></links><search><creatorcontrib>Masibag, Angelique N.</creatorcontrib><creatorcontrib>Bergin, Christopher J.</creatorcontrib><creatorcontrib>Haebe, Joshua R.</creatorcontrib><creatorcontrib>Zouggar, Aïcha</creatorcontrib><creatorcontrib>Shah, Muhammad S.</creatorcontrib><creatorcontrib>Sandouka, Tamara</creatorcontrib><creatorcontrib>Mendes da Silva, Amanda</creatorcontrib><creatorcontrib>Desrochers, François M.</creatorcontrib><creatorcontrib>Fournier-Morin, Aube</creatorcontrib><creatorcontrib>Benoit, Yannick D.</creatorcontrib><title>Pharmacological targeting of Sam68 functions in colorectal cancer stem cells</title><title>iScience</title><description>Cancer stem cells (CSCs) are documented to play a key role in tumorigenesis and therapy resistance. Despite significant progress in clinical oncology, CSC reservoirs remain elusive and difficult to eliminate. Reverse-turn peptidomimetics were characterized as disruptors of CBP/beta-Catenin interactions and represent a promising avenue to curb hyperactive canonical Wnt/beta-Catenin signaling in CSCs. Recent studies suggested Sam68 as a critical mediator of reverse-turn peptidomimetics response in CSC populations. Using computational and biochemical approaches we confirmed Sam68 as a primary target of reverse-turn peptidomimetics. Furthermore, we executed an in silico drug discovery pipeline to identify yet uncharacterized reverse-turn peptidomimetic structures displaying superior anti-CSC activity in transformed pluripotent and colorectal cancer cell models. Thus, we identified YB-0158 as a reverse-turn peptidomimetic small molecule with enhanced translational potential, altering key hallmarks of human colorectal CSCs in patient-derived ex vivo organoids and in vivo serial tumor transplantation.
[Display omitted]
•Sam68 is a direct protein target of reverse-turn peptidomimetic small molecules•YB-0158 is a peptidomimetic structure with high predicted affinity for Sam68•YB-0158 elicits a cancer-selective response impeding main cancer stem cell hallmarks•YB-0158 blocks cancer stem cell activity in tumor organoids and in vivo systems
Pharmacology; Biochemistry; Stem cells research; Cancer;</description><subject>Biochemistry</subject><subject>Cancer</subject><subject>Pharmacology</subject><subject>Stem cells research</subject><issn>2589-0042</issn><issn>2589-0042</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNp9UV1rFDEUDWKxZds_4NM8-rJrvjbJgAhSrBYWFGyfw82dzDTLzKQm2YL_3oxTxL4IIfdy7zkn5BxC3jK6Y5Sp98ddyBh2nHJWB0JK_opc8L1pt5RK_vqf_pxc5XyklPJ6ZKvekHMhjdaybS_I4fsDpAkwjnEICGNTIA2-hHloYt_8gEmZpj_NWEKccxPmZkEmj6VCEWb0qcnFTw36ccyX5KyHMfur57oh9zef766_bg_fvtxefzpsUbambJWjUqOSnRbQSQAOVBnmFRNOdwL2Spk6N7xzwKiR2KFyyFmv9hIBWy425HbV7SIc7WMKE6RfNkKwfwYxDRZSCTh6C9IJJXtgzmhJfS0deidAa107t2h9XLUeT27ydTmXBOML0ZebOTzYIT5Zo4Ro67Uh754FUvx58rnYqSZT7YDZx1O2XFHDuJQtrVC-QjHFnJPv_z7DqF1StUe7pGqXVO2aaiV9WEm-OvoUfLIV4avzXVhyqF8O_6P_BhWaqmg</recordid><startdate>20211217</startdate><enddate>20211217</enddate><creator>Masibag, Angelique N.</creator><creator>Bergin, Christopher J.</creator><creator>Haebe, Joshua R.</creator><creator>Zouggar, Aïcha</creator><creator>Shah, Muhammad S.</creator><creator>Sandouka, Tamara</creator><creator>Mendes da Silva, Amanda</creator><creator>Desrochers, François M.</creator><creator>Fournier-Morin, Aube</creator><creator>Benoit, Yannick D.</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-0832-5753</orcidid><orcidid>https://orcid.org/0000-0002-4631-5812</orcidid><orcidid>https://orcid.org/0000-0003-3610-6184</orcidid><orcidid>https://orcid.org/0000-0002-6677-4020</orcidid></search><sort><creationdate>20211217</creationdate><title>Pharmacological targeting of Sam68 functions in colorectal cancer stem cells</title><author>Masibag, Angelique N. ; Bergin, Christopher J. ; Haebe, Joshua R. ; Zouggar, Aïcha ; Shah, Muhammad S. ; Sandouka, Tamara ; Mendes da Silva, Amanda ; Desrochers, François M. ; Fournier-Morin, Aube ; Benoit, Yannick D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c498t-6b047c64d73ad4aa2a0681e613b7d3a5668ad482dba1084cdc6bc21f654cac923</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Biochemistry</topic><topic>Cancer</topic><topic>Pharmacology</topic><topic>Stem cells research</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Masibag, Angelique N.</creatorcontrib><creatorcontrib>Bergin, Christopher J.</creatorcontrib><creatorcontrib>Haebe, Joshua R.</creatorcontrib><creatorcontrib>Zouggar, Aïcha</creatorcontrib><creatorcontrib>Shah, Muhammad S.</creatorcontrib><creatorcontrib>Sandouka, Tamara</creatorcontrib><creatorcontrib>Mendes da Silva, Amanda</creatorcontrib><creatorcontrib>Desrochers, François M.</creatorcontrib><creatorcontrib>Fournier-Morin, Aube</creatorcontrib><creatorcontrib>Benoit, Yannick D.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Open Access: DOAJ - Directory of Open Access Journals</collection><jtitle>iScience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Masibag, Angelique N.</au><au>Bergin, Christopher J.</au><au>Haebe, Joshua R.</au><au>Zouggar, Aïcha</au><au>Shah, Muhammad S.</au><au>Sandouka, Tamara</au><au>Mendes da Silva, Amanda</au><au>Desrochers, François M.</au><au>Fournier-Morin, Aube</au><au>Benoit, Yannick D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacological targeting of Sam68 functions in colorectal cancer stem cells</atitle><jtitle>iScience</jtitle><date>2021-12-17</date><risdate>2021</risdate><volume>24</volume><issue>12</issue><spage>103442</spage><epage>103442</epage><pages>103442-103442</pages><artnum>103442</artnum><issn>2589-0042</issn><eissn>2589-0042</eissn><abstract>Cancer stem cells (CSCs) are documented to play a key role in tumorigenesis and therapy resistance. Despite significant progress in clinical oncology, CSC reservoirs remain elusive and difficult to eliminate. Reverse-turn peptidomimetics were characterized as disruptors of CBP/beta-Catenin interactions and represent a promising avenue to curb hyperactive canonical Wnt/beta-Catenin signaling in CSCs. Recent studies suggested Sam68 as a critical mediator of reverse-turn peptidomimetics response in CSC populations. Using computational and biochemical approaches we confirmed Sam68 as a primary target of reverse-turn peptidomimetics. Furthermore, we executed an in silico drug discovery pipeline to identify yet uncharacterized reverse-turn peptidomimetic structures displaying superior anti-CSC activity in transformed pluripotent and colorectal cancer cell models. Thus, we identified YB-0158 as a reverse-turn peptidomimetic small molecule with enhanced translational potential, altering key hallmarks of human colorectal CSCs in patient-derived ex vivo organoids and in vivo serial tumor transplantation.
[Display omitted]
•Sam68 is a direct protein target of reverse-turn peptidomimetic small molecules•YB-0158 is a peptidomimetic structure with high predicted affinity for Sam68•YB-0158 elicits a cancer-selective response impeding main cancer stem cell hallmarks•YB-0158 blocks cancer stem cell activity in tumor organoids and in vivo systems
Pharmacology; Biochemistry; Stem cells research; Cancer;</abstract><pub>Elsevier Inc</pub><pmid>34877499</pmid><doi>10.1016/j.isci.2021.103442</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-0832-5753</orcidid><orcidid>https://orcid.org/0000-0002-4631-5812</orcidid><orcidid>https://orcid.org/0000-0003-3610-6184</orcidid><orcidid>https://orcid.org/0000-0002-6677-4020</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2589-0042 |
ispartof | iScience, 2021-12, Vol.24 (12), p.103442-103442, Article 103442 |
issn | 2589-0042 2589-0042 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_a4b364fa1b8740e1b8dceb3a7778dcb2 |
source | ScienceDirect®; NCBI_PubMed Central(免费) |
subjects | Biochemistry Cancer Pharmacology Stem cells research |
title | Pharmacological targeting of Sam68 functions in colorectal cancer stem cells |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T12%3A16%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacological%20targeting%20of%20Sam68%20functions%20in%20colorectal%20cancer%20stem%20cells&rft.jtitle=iScience&rft.au=Masibag,%20Angelique%20N.&rft.date=2021-12-17&rft.volume=24&rft.issue=12&rft.spage=103442&rft.epage=103442&rft.pages=103442-103442&rft.artnum=103442&rft.issn=2589-0042&rft.eissn=2589-0042&rft_id=info:doi/10.1016/j.isci.2021.103442&rft_dat=%3Cproquest_doaj_%3E2608124490%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c498t-6b047c64d73ad4aa2a0681e613b7d3a5668ad482dba1084cdc6bc21f654cac923%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2608124490&rft_id=info:pmid/34877499&rfr_iscdi=true |